[go: up one dir, main page]

CR20230198A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Info

Publication number
CR20230198A
CR20230198A CR20230198A CR20230198A CR20230198A CR 20230198 A CR20230198 A CR 20230198A CR 20230198 A CR20230198 A CR 20230198A CR 20230198 A CR20230198 A CR 20230198A CR 20230198 A CR20230198 A CR 20230198A
Authority
CR
Costa Rica
Prior art keywords
modulators
cystic fibrosis
conductance regulator
transmembrane conductance
fibrosis transmembrane
Prior art date
Application number
CR20230198A
Other languages
English (en)
Inventor
Jeremy Clemens
Anton V Gulevich
Yoshihiro Ishihara
Mark Thomas Miller
Lev Tyler Dewey Fanning
Alexander Russell Abela
Peter Grootenhuis
Ruah Sara Sabina Hadida
Haripada Khatuya
Prasuna Paraselli
Corey Don Anderson
Bryan A Frieman
Jinglan Zhou
Jason Mccartney
Sunny Abraham
Jaclyn Chau
Thomas Cleveland
Vito Melillo
Troy Vickers
Paul Krenitsky
Vijayalaksmi Arumugam
Fabrice Pierre
Joe A Tran
Alina Silina
Timothy A Dwight
Timothy Richard Coon
Johnny Uy
Lino Valdez
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20230198A publication Critical patent/CR20230198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<br /> <br /> La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.
CR20230198A 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística CR20230198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088686P 2020-10-07 2020-10-07
PCT/US2021/053858 WO2022076622A2 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
CR20230198A true CR20230198A (es) 2023-07-03

Family

ID=80091350

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230198A CR20230198A (es) 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Country Status (19)

Country Link
US (1) US20240150377A1 (es)
EP (1) EP4225765A2 (es)
JP (1) JP2023545080A (es)
KR (1) KR20230107725A (es)
CN (1) CN116601158A (es)
AR (1) AR123708A1 (es)
AU (1) AU2021358512A1 (es)
CA (1) CA3197683A1 (es)
CL (1) CL2023000988A1 (es)
CO (1) CO2023005006A2 (es)
CR (1) CR20230198A (es)
DO (1) DOP2023000067A (es)
EC (2) ECSP23032843A (es)
IL (1) IL301757A (es)
MX (1) MX2023004072A (es)
PE (1) PE20231108A1 (es)
TW (1) TW202229298A (es)
UY (1) UY39457A (es)
WO (1) WO2022076622A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
US12186306B2 (en) 2020-12-10 2025-01-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
KR20240144973A (ko) 2022-02-03 2024-10-04 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
CR20240457A (es) * 2022-04-06 2024-12-11 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AU2023273614A1 (en) 2022-05-16 2024-11-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2024054840A1 (en) * 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions, and methods of using thereof
WO2024054845A1 (en) * 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
TW202421636A (zh) * 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
CN116143722B (zh) * 2023-03-09 2024-05-31 南京师范大学 一种次磺酰胺类化合物的合成工艺
CN119191996A (zh) * 2024-11-28 2024-12-27 浙江省质量科学研究院 一种双羟乙基氨基丙基羟乙基油胺的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2005258320B2 (en) 2004-06-24 2010-09-16 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
ES2625957T3 (es) 2007-12-07 2017-07-21 Vertex Pharmaceuticals Incorporated Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
EP3345625B1 (en) 2008-08-13 2020-12-09 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
KR20110063578A (ko) 2008-09-29 2011-06-10 버텍스 파마슈티칼스 인코포레이티드 3－（6－（1－（2,2－디플루오로벤조［ｄ］［1,3］디옥솔－5－일）사이클로프로판카복스아미도）－3－메틸피리딘－2－일）벤조산의 투여 단위
PL2365972T3 (pl) 2008-11-06 2015-05-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
CN109081804B (zh) 2010-03-25 2021-12-10 弗特克斯药品有限公司 环丙烷甲酰胺的固体形式
CA2796088C (en) 2010-04-09 2018-02-06 Ekso Bionics Exoskeleton load handling system and method of use
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
EP3138563A1 (en) 2010-04-22 2017-03-08 Vertex Pharmaceuticals Inc. Pharmaceutical compositions and administrations thereof
NZ607494A (en) 2010-08-27 2015-04-24 Vertex Pharma Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
RS56096B1 (sr) 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
RS57831B2 (sr) 2012-11-02 2024-02-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
HUE039062T2 (hu) 2014-04-15 2018-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
SMT202000540T1 (it) * 2014-10-06 2020-11-10 Vertex Pharma Modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
EP3352757B1 (en) 2015-09-21 2023-08-16 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2018080591A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
US11066417B2 (en) * 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
BR112021011643A2 (pt) * 2018-12-21 2021-09-08 Novartis Ag Compostos macrocíclicos e seu uso no tratamento de doença
AR118555A1 (es) * 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Also Published As

Publication number Publication date
UY39457A (es) 2022-05-31
PE20231108A1 (es) 2023-07-19
ECSP23032843A (es) 2023-06-30
CN116601158A (zh) 2023-08-15
KR20230107725A (ko) 2023-07-17
US20240150377A1 (en) 2024-05-09
MX2023004072A (es) 2023-07-05
IL301757A (en) 2023-05-01
WO2022076622A3 (en) 2022-07-21
WO2022076622A2 (en) 2022-04-14
JP2023545080A (ja) 2023-10-26
CL2023000988A1 (es) 2023-09-15
AU2021358512A1 (en) 2023-05-18
AR123708A1 (es) 2023-01-04
TW202229298A (zh) 2022-08-01
CA3197683A1 (en) 2022-04-14
ECSP23033092A (es) 2023-06-30
EP4225765A2 (en) 2023-08-16
CO2023005006A2 (es) 2023-09-08
DOP2023000067A (es) 2023-07-09
AU2021358512A9 (en) 2024-10-24
AU2021358512A8 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
CR20230198A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CL2023000375A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2023005734A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39458A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
MX2022001827A (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
UY39459A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39456A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39461A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39455A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
CR20230260A (es) Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CL2024003000A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39521A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística